When should children with HIV infection be started on antiretroviral therapy? by Welch, Steven B & Gibb, Di
PLoS Medicine  |  www.plosmedicine.org 0335 March 2008  |  Volume 5  |  Issue 3  |  e73
The PLoS Medicine Debate
Background to the debate: The advent of highly active antiretroviral therapy (HAART) dramatically improved 
the prognosis for both adults and children infected with HIV 
who had access to treatment. However, the optimal timing 
for initiating treatment remains controversial, particularly 
in children. This debate lays out the case for deferred 
treatment against the case for early initiation of HAART in 
children.
Steven Welch’s Viewpoint: The Case for 
Deferring Treatment
Combination antiretroviral therapy (ART) has transformed 
paediatric HIV infection in developed countries in the last 
decade, and has the potential to do so worldwide. Paediatric 
HIV has gone from being universally fatal to becoming a 
treatable chronic condition. A child diagnosed with HIV in 
a developed country in 2007 would be expected to survive 
into adulthood, largely thanks to ART. With the privilege 
of being able to prescribe such successful treatment comes 
the responsibility of using it wisely. When they leave our 
care for adult clinics, our paediatric patients should have 
been optimally treated and have a good understanding of 
their condition. The hasty and injudicious use of ART risks 
creating a cohort that has learned poor adherence habits, 
is infected with multi-drug-resistant viruses, and has been 
exposed to unnecessary cumulative drug toxicities.
Infants are unique because of their high susceptibility 
to life-threatening opportunistic infections or irreversible 
brain damage from HIV encephalopathy during a critical 
developmental period. Their CD4 counts and percentages 
are also less dependable predictors of complications at this 
age. There is thus an increasing consensus and supporting 
evidence in favour of early, perhaps universal treatment 
of children aged less than one year [1]. However, we treat 
infants in the confessed knowledge that 80% of them do 
not have rapidly progressive disease, accepting that we are 
not good enough at recognising complications such as 
encephalopathy before irreversible damage has been done. 
Beyond infancy, we should delay treatment until it is really 
needed—for children older than a year, rapid progression 
without easily detectable clinical changes or a fall in CD4 
count is less likely.
Ideally, we would base our decision on when to start 
treatment on data from randomised controlled trials, but 
these do not exist. In their absence, it is tempting to get all 
children established on treatment. Are there any reasons not 
to do this? On the principle of “Primum non nocere” (First, 
do no harm), we should not treat children unless there is 
evidence they will benefit. But what harm can ART do?
Children diagnosed with HIV may now live for many 
decades. There are no data on the cumulative effects of 
taking ART for decades, because these drug combinations 
have only been available for just over one decade. But it 
is clear that some side effects, particularly dyslipidaemias 
and the accumulation of cardiovascular risk, do depend on 
duration of drug exposure. Anything we can do to lessen 
this duration must be beneficial. Structured treatment 
interruptions for adult patients went out of favour following 
the results of the recent Strategies for Management of 
Antiretroviral Therapy (SMART) study [2]. In the SMART 
study, structured treatment interruptions significantly 
increased the risk of opportunistic diseases or death from 
any cause, as compared with continuous ART. We await 
the outcome of the PENTA 11 study (Paediatric European 
Network for Treatment of AIDS) of treatment interruptions 
in children (see http:⁄⁄www.pentatrials.org/trials.
htm#penta11), but for now we must assume that once a child 
has been started on treatment it is likely to be lifelong. The 
only way of minimising drug exposure is therefore to avoid 
starting treatment too early.
The effect of taking ART on family life cannot be 
overstated. Sadly, HIV remains a stigmatised condition, and 
many families choose not to disclose their diagnosis to even 
close contacts. The mere presence of medication in the house 
risks accidental discovery and inadvertent disclosure. Most 
schools are not aware of children’s diagnoses, and sending 
children to sleepovers or on school trips may become a major 
problem. Many families report missing doses when they 
cannot be taken unobserved rather than risking discovery. 
Unlike other chronic conditions, successful treatment of 
HIV requires drug adherence rates of the order of 95% 
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[3]. Failure to achieve this risks rapid evolution of drug-
resistant virus. Palatable paediatric syrups and appropriate 
low-dose tablet formulations remain all too rare, meaning 
that adherence is more difficult for children than adults. 
Add in the difficult social situations of many families living 
with HIV, and the fact that some paediatric antiretroviral 
syrups still need refrigeration, and it is clear that maintaining 
drug adherence can be a massive undertaking. Imposing this 
burden if it is not truly necessary creates a risk of learned 
poor drug adherence practices, and the limitation of future 
treatment options because of drug resistance.
Worldwide, the greatest obstacle to ready availability of 
ART for children is cost, and where drugs are readily available 
we have the responsibility to use them wisely. This includes 
not wasting this expensive resource when it is not really 
indicated. ART should never be initiated lightly in children, 
and, beyond infancy, should only be started when the 
individual child’s clinical condition and CD4 count indicate a 
clear likelihood of the benefit outweighing the possible harm.
At which CD4 count this benefit occurs is not clear. We rely 
on cohort data from before the era of HAART to inform us 
of the risk of short-term disease progression for a child of a 
given age with a particular CD4 count [4,5]. But we have no 
data on the long-term outcomes of starting ART at different 
CD4 counts. It therefore remains rational to consider an 
individual child’s and family’s wishes and circumstances as 
well as the child’s risk of disease progression in deciding 
when to start treatment, rather than using a rigidly set CD4 
threshold.
Di Gibb’s Viewpoint: The Case for Earlier 
Initiation
The debate about when to start ART has raged since 
effective triple combination ART became available over a 
decade ago. At that time, the hope of HIV eradication fuelled 
enthusiasm for liberal use of ART [6]. However, with the 
rapid realisation that HIV could not be cured, and fears about 
toxicity of early drugs and HIV resistance, in the late 1990s, 
there was a swing to the other extreme—starting ART “as late 
as possible” [7].
In the last eight years, arguments for delaying ART have 
become weaker and those favouring earlier ART have 
strengthened for both adults and children. New evidence 
shows that progression to AIDS and, in particular, serious 
non-AIDS events (cardiac, renal, hepatic) occur at higher 
CD4 thresholds than previously thought [2]. This is 
particularly true for middle-income countries and resource-
limited settings, where most HIV-infected children live [8]. 
Moreover, early fears about long-term drug toxicity were 
probably overplayed [9]; more appropriate, simpler drug 
regimens have become increasingly available, resulting in 
year-on-year improvements in durable viral load responses 
[10]. Finally, triple-class drug resistance appears less common 
than originally anticipated [11], and two new classes of drugs, 
with no cross-resistance, have recently become available. 
The goals of ART are to save lives, decrease morbidity, 
minimise toxicity, and maximise quality of life. For HIV-
infected children, there is also the need to achieve full 
future potential as adults, in terms of growth, pubertal 
development, and neurodevelopment. I would argue that 
earlier ART for children is even more important than for 
adults for five reasons. First, HIV disease progression is faster 
in young children than in adults [12]. Second, significant 
immune recovery is better in younger children in whom the 
thymus is more active [10,13]. Third, bacterial infections 
are most common and serious in younger children, occur 
at high CD4 values, and are reduced by ART [14]; the same 
is true for tuberculosis, of particular relevance to resource-
limited settings [15]. Fourth, better growth occurs if ART is 
started early; untreated children are ten centimetres shorter 
than their uninfected peers by age ten years [16], and short 
stature may be harder to reverse when ART is started at 
older ages. Fifth, HIV encephalopathy is a particular concern 
for children exposed to HIV during brain development; 
early ART initiation appears to reduce HIV encephalopathy 
compared to historical controls in infants [1,17], and may 
also reduce more subtle neurological problems in older 
children.
In addition to these arguments, many of which are based 
on data from cohort studies, which can be prone to several 
forms of bias, new randomised evidence has recently been 
presented that reinforces the arguments for earlier ART. 
Initial data from the Children with HIV Early Antiretroviral 
Therapy (CHER) trial recently showed a highly significant 
76% reduction in mortality in infants initiating ART 
before 12 weeks of age, compared with starting when CD4 
percentages fell below 25% or clinical symptoms developed 
[1]. Of note, deaths were sudden and often not strictly AIDS-
defining. CHER is continuing, with the objective of evaluating 
the long-term effects of early limited ART; young infants in 
the deferred arm have been started on ART.
What about children after infancy? Risk of disease 
progression decreases with age in childhood [18,19], so 
first let us consider children over five years. Evidence from 
a recent study combining data on untreated children over 
five years from the HIV Paediatric Prognostic Markers 
Collaborative Study [18,19] and data from adults (Concerted 
Action on SeroConversion to AIDS and Death in Europe, 
CASCADE) shows that the risk of disease progression 
according to current CD4 cell count (rather than CD4 
percentage, as used in younger children) is almost identical 
in a five-year-old and in a young adult [20]. Thus, any 
arguments suggesting that ART should be initiated earlier in 
adults are of equal relevance to older children. 
New randomised evidence has recently been presented 
from a subgroup of about 500 adults who were ART naïve 
or had not received ART for over six months at enrolment 
in the SMART trial [21]. Patients with CD4 counts over 
350 cells/mm3 randomised to delay ART had a significant 
(approximately 5-fold) increased risk of both AIDS and 
serious non-AIDS events compared with those starting ART 
at CD4 counts over 350 cells/mm3. In effect, this was a mini 
“when to start” randomised trial. These data are further 
supported by recent cohort analyses showing a continuum 
of decreasing disease progression among patients not on 
ART at CD4 cell counts below 350 compared with those with 
CD4 counts between 350–500, in turn compared with those 
with CD4 counts above 500 [22]. This suggests the need for 
revision of adult and older children guidelines to advocate 
ART initiation by the time a patient’s CD4 count has reached 
350 cells/mm3, rather than when it is between 200–250 
cells/mm3, as previously recommended [23,24]. Randomised 
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trials are also needed, and could include older children, but 
should focus on evaluating starting ART at even higher CD4 
counts [25]. 
Finally, I appreciate that the prospect of “therapy for life” 
is daunting for caregivers and paediatricians. Nevertheless, 
it is important to remember that short stature, delayed 
puberty, and difficulties with school—both academic and 
social—can only add to the miseries of living with HIV during 
adolescence, which is anyway a time when adherence to 
drugs becomes worse. Therefore, rather than deferring ART 
for as long as possible, I would argue that a better strategy 
might be to maximise the potential of ART to fully suppress 
viral load and to normalise the immune system, growth, 
and neurodevelopment during early childhood when carers 
can more easily supervise ART, followed by simplifying or 
even interrupting regimens during adolescence (if ongoing 
trials such as PENTA 11 show this is safe). We need trials to 
evaluate starting ART at even higher CD4 counts (in older 
children) and higher CD4 percentages in younger children, 
and more work is needed to compare the predictive value 
of CD4 count and percentage in young children. In the 
meantime, deferring treatment initiation for as long as 
possible is no longer an option, and paediatric guidelines 
need to be updated now. Indeed, European adult guidelines 
now recommend ART initiation at CD4 counts below 350 
cells/mm3 [26].
Steven Welch’s Response to Di Gibb’s Viewpoint
The most convincing data in favour of early treatment 
come from adults and infants, and there are good reasons 
why these may not apply to older children. Professor Gibb’s 
other arguments for early initiation of ART in children are 
based on the perceived safety of new drug regimens, the need 
to maximise children’s growth and developmental potential, 
and the risk of clinical progression. 
Adults starting ART have poorer immune reconstitution 
if they start at low CD4 counts, but in children, long-term 
immune reconstitution is independent of CD4 count [27,28] 
or age [28] at start of treatment. Starting treatment at young 
age does increase the risk of poor virological response, and 
hence resistance [13]. Professor Gibb argues that data from 
the SMART study [21] on treatment thresholds in adults can 
be applied to children, based on pre-HAART comparisons of 
CD4-related short-term AIDS progression risks in adults and 
children [20]. But similar progression risks do not equate 
to similar benefits from treatment. Much of the benefit 
from treatment in the SMART study was from avoidance of 
non-AIDS events. These include cardiovascular events and 
malignancies, which occur much less commonly in children 
than in adults.
The recent advent of new drugs and drug classes to treat 
HIV is very welcome, but we must be wary of excessive 
therapeutic optimism. The advent of HAART was followed 
by a trend for its early use, followed by a swing to the other 
extreme. Children starting ART will be taking drugs for 
decades, and we cannot be certain about long-term safety 
after a couple of years.
The risks of rapid disease progression, including 
encephalopathy, are alone enough to warrant aggressive 
early treatment of HIV in infants. The data from the CHER 
trial [1] further reinforce this argument, but make no 
contribution to the debate in older children. Many factors 
contribute to poor nutritional, growth, and developmental 
outcomes in children with HIV, and a far broader approach 
than the provision of ART will be required to optimise these 
outcomes.
The fact that guidelines have fluctuated so much over 
time between recommending early and late treatment 
demonstrates that we still do not know the right time to 
start. There are good reasons not to extrapolate adult and 
infant data to older children. What is needed is a proper 
randomised trial of thresholds for initiating treatment in 
children [29]. Until the results of such a trial are available, it 
remains appropriate to decide the right time on an individual 
basis for each child and their family, taking into account the 
family’s wishes and circumstances as well as the child’s CD4 
count.
Di Gibb’s Response to Steven Welch’s Viewpoint
Dr. Welch agrees that there is good evidence for starting 
early ART in infants [1]. Data in adults are also compelling, as 
evidenced from recent presentations at the 2008 Conference 
on Retroviruses and Opportunistic Infections (http:⁄⁄www.
retroconference.org/2008/) showing that non-AIDS serious 
events at high CD4 cell counts may well be HIV-related rather 
than drug-related [30]. For well-resourced settings, adult 
guidelines have recently changed to recommend treatment 
initiation in individuals with CD4 counts of less than 350 
cells/mm3 (previously those with CD4 cell counts of between 
200–350 cells/mm3 were “for consideration of ART” rather 
than “recommended”). As I have argued, children over five 
years in well-resourced settings have similar risks of disease 
progression as young adults at the same CD4 count [20]. It is 
untenable for older children to initiate ART later than adults. 
Indeed, new US data suggest that, as in adults, CD4 recovery 
in children may be related to the baseline CD4 count before 
initiating HAART: recovery is poorer if the CD4 percentage 
is under 15% [31]. The risk of disease progression is higher 
in one-to-five-year-olds than older children; it follows that 
the CD4 thresholds for ART initiation in one-to-five-year-olds 
should be higher to reflect this greater risk. 
Poor availability of ARV drug formulations is not a reason 
to defer ART. Rather, arguments for the need for therapy 
should spur paediatricians and children’s activists to lobby 
pharmaceutical companies to make more appropriate drug 
formulations and ensure timely availability of paediatric 
pharmacokinetic data. New European law and World Health 
Organization recommendations on use of simplified dosing 
tables based on weight-bands, derived from body surface area, 
should help in this regard [32]. Both originator and generic 
pharmaceutical companies are beginning to respond to such 
lobbying.
There remains an urgent need for large randomised trials 
on timing of ART initiation in both well-resourced and 
resource-limited countries. In well-resourced settings, I would 
argue that evaluating ART initiation at high CD4 counts 
versus below the 350 cells/mm3 CD4 count threshold in older 
children and adults would be appropriate. A separate trial 
with higher control thresholds (as CD4 percentage) is needed 
for children aged one to five years. Neurodevelopmental 
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and growth evaluations would be key endpoints for children. 
For resource-limited settings, issues include the role of ART 
in reducing HIV transmission, prevention of tuberculosis, 
and malnutrition [8]. Separate trials on the “when to 
start” question in resource-limited settings need to address 
these issues. In addition, when choosing thresholds here, 
consideration must also be given to ART availability and 
cost-effectiveness, as currently fewer than 20% of sick adults 
and even fewer children in urgent need of ART receive such 
treatment.
Paediatric guidelines for infants in the first year of 
life should now recommend universal ART where infant 
diagnosis is available; implementation and cost-effectiveness 
need examining in settings where early diagnosis is not 
available. Finally, the question about whether ART can be 
stopped after having been started soon after seroconversion 
in all infants needs to be addressed.
References
1. Violari A, Cotton M, Gibb D (2007) Antiretroviral therapy initiated before 
12 weeks of age reduces early mortality in young HIV-infected infants: 
Evidence from the Children with HIV Early Antiretroviral Therapy (CHER) 
Study [Abstract WESS103]. 4th IAS Conference on HIV Pathogenesis, 
Treatment, and Prevention; 22-25 July 2007; Sydney, Australia. Available: 
http://www.ias2007.org/pag/Abstracts.aspx?AID=5557. Accessed 15 
February 2008.
2. The Strategies for Management of Antiretroviral Therapy (SMART) Study 
Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, et al. (2006) CD4+ 
count-guided interruption of antiretroviral treatment. N Engl J Med 355: 
2283-2296
3. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. (2000) 
Adherence to protease inhibitor therapy and outcomes in patients with HIV 
infection. Ann Intern Med 133: 21-30.
4. Dunn D; HIV Paediatric Prognostic Markers Collaborative Study Group 
(2003) Short-term risk of disease progression in HIV-1-infected children 
receiving no antiretroviral therapy or zidovudine monotherapy: A meta-
analysis. Lancet 362: 1605–1611.
5. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM on behalf of the 
PENTA Steering Committee (2004) PENTA guidelines for the use of 
antiretroviral therapy, 2004. HIV Med 5 (Suppl 2): 61-86.
6. Ho D (1995) Time to hit HIV, early and hard. New Engl J Med 333: 450-451.
7. Harrington M, Carpenter CCJ (2000) Hit HIV-1 hard, but only when 
necessary. Lancet 355: 2147-2152.
8. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing 
Committee (2008) Markers for predicting mortality in untreated HIV-
infected children in resource-limited settings: A meta-analysis. AIDS 22: 97-
105.
9. The DAD Study Group (2007) DAD publications. Available: http://www.
cphiv.dk/DAD/Publications/tabid/111/Default.aspx. Accessed 15 February 
2008.
10. Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, et al. (2007) 
Morbidity, mortality, and response to treatment by children in the United 
Kingdom and Ireland with perinatally acquired HIV infection during 
1996-2006: Planning for teenage and adult care. Clin Infect Dis 45: 918-
924.
11. Phillips AN, Wilson A, Leen C (2007) Cumulative risk of extensive triple-
class virologic failure in 10,603 patients followed as long as 10 years from 
the start of ART [Abstract 532]. 14th Conference on Retroviruses and 
Opportunistic Infections; 25-28 February 2007; Los Angeles, California, 
United States. Available: http://www.retroconference.org/2007/
Abstracts/29079.htm. Accessed 15 February 2008.
12. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, et al. (1998) Disease 
progression in HIV infected infants and children: Predictive value of 
quantitative plasma HIV RNA and CD4 lymphocyte count. JAMA 279:756-
761.
13. Walker AS, Doerholt K, Sharland M, Gibb DM; Collaborative HIV Paediatric 
Study (CHIPS) Steering Committee (2004) Response to highly active 
antiretroviral therapy varies with age: The UK and Ireland Collaborative 
HIV Paediatric Study. AIDS 18: 1915-1924.
14. Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, et al. 
(2007) Trends in opportunistic infections in the pre- and post-highly active 
antiretroviral therapy eras among HIV-infected children in the Perinatal 
AIDS Collaborative Transmission Study, 1986-2004. Pediatrics 120: 100-109.
15. Lawn SD, Myer L, Bekker LG, Wood R (2006) Burden of tuberculosis in 
an antiretroviral treatment programme in sub-Saharan Africa: Impact 
on treatment outcomes and implications for tuberculosis control. AIDS 
20:1605-1612.
16. European Collaborative Study (1995) Weight, height and human 
immunodeficiency virus infection in young children of infected mothers. 
Pediatr Infect Dis J 14: 685-690.
17. Faye A, Le Chenadec J, Dollfus C, Thuret I, Douard D, et al. (2004) Early 
versus deferred antiretroviral multidrug therapy in infants infected with 
HIV type 1. Clin Infect Dis 39: 1692-1698.
18. Dunn DT, Gibb DM, Duong T for the HIV Paediatric Prognostic Markers 
Collaborative Study Group (2003) Short-term risk of disease progression in 
HIV-1 infected children receiving no antiretroviral therapy or zidovudine 
monotherapy: A meta-analysis. Lancet 362: 1605-1611.
19. Dunn DT, Gibb DM, Duong T for the HIV Paediatric Prognostic Markers 
Collaborative Study Group (2006) Predictive value of absolute CD4 cell 
count for disease progression in untreated HIV-1-infected children. AIDS 
20: 1289-1294.
20. Dunn DT, Woodburn P, Duong T, Peto J, Phillips P, et al. for the HIV 
Paediatric Prognostic Markers Collaborative Study and the CASCADE 
Collaboration (2008) Current CD4 cell count and the short-term risk of 
AIDS and death before the availability of effective antiretroviral therapy in 
HIV-infected children and adults. J Infect Dis 197: 398-404.
21. Emery S, SMART Study Group, INSIGHT. Major clinical outcomes in 
patients not treated with antiretroviral therapy at baseline in SMART: A 
rationale for a trial to examine early treatment of HIV disease [Abstract 
WEPEB018]. 4th IAS Conference on HIV Pathogenesis, Treatment, and 
Prevention; 22-25 July 2007; Sydney, Australia. Available: http://www.
ias2007.org/pag/Abstracts.aspx?AID=3978. Accessed 15 February 2008.
22. The UK CHIC Study Steering Committee (2007) Rate of AIDS diseases or 
death in HIV infected individuals with high CD4 count. AIDS 21: 1717-1721.
23. Hammer SM, Saag MS, Schechter M, Montaner JSG, Scholley RT, et al. 
(2006) Treatment for adult HIV infection. 2006 recommendations of the 
International AIDS Society–USA Panel. JAMA 296: 827-843.
24. British HIV Association (2006) Treatment of HIV-infected adults with 
antiretroviral therapy. Available: http://www.bhiva.org/cms1191541.asp. 
Accessed 15 February 2008.
25. Gordin F (2007) Is an early treatment study important now? [Abstract 
MOSY205]. 4th IAS Conference on HIV Pathogenesis, Treatment, and 
Prevention; 22-25 July 2007; Sydney, Australia. Available: . Accessed 15 
February 2008. Available: http://www.ias2007.org/pag/PSession.aspx?s=18. 
Accessed 15 February 2008.
26. European AIDS Clinical Society (2007) Guidelines for the clinical 
management and treatment of HIV-infected adults in Europe. Available: 
http://www.eacs.eu/guide/1_Treatment_of_HIV_Infected_Adults.pdf.
Accessed 15 February 2008.
27. Newell ML, Patel D, Goetghebuer T, Thorne C; European Collaborative 
Study (2006) CD4 cell response to antiretroviral therapy in children with 
vertically acquired HIV infection: Is it associated with age at initiation? J 
Infect Dis 193: 954-962
28. Van Rossum AM, Scherpbier HJ, van Lochem EG, Pakker NG, Slieker 
WA for the Dutch Study Group for Children with HIV Infections (2001) 
Therapeutic immune reconstitution in HIV-1-infected children is 
independent of their age and pre-treatment immune status, AIDS 15: 2267-
2275.
29. Verweel G, Saavedra-Lozano J, van Rossum AM, Ramilo O, de Groot 
R (2006) Initiating highly active antiretroviral therapy in human 
immunodeficiency virus type 1-infected children in Europe and the United 
States: Comparing clinical practice to guidelines and literature evidence. 
Pediatr Infect Dis J 25: 987-994.
30. Phillips A (2008) Morbidity and mortality in the HAART Era 
[presentation]. 15th Conference on Retroviruses and Opportunistic 
Infections; 3–6 February 2008; Boston, Massachusetts, United States. 
Available: http://www.retroconference.org/2008/data/files/retro2008_
frameset.htm. Accessed 15 February 2008.
31. Patel K et al. (2008) Recovery of immune status with HAART is dependent 
on CD4% at time HAART is initiated. Clin Infect Dis. In press.
32. World Health Organization (2006) Antiretroviral therapy of HIV infection 
in infants and children in resource-limited settings: Towards universal 
access. Recommendations for a public health approach. Available: http://
www.who.int/hiv/pub/guidelines/art/en/. Accessed 15 February 2008.
